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Abstract:  The synthesis of two new families of amino acid-containing chiral ligands, based on 
methyliminodiacetic acid and nitrilotriacetic acid cores, has been accomplished using a simple 
protection, solution phase amide coupling and deprotection strategy.  The amino acids glycine, leucine, 
aspartic acid and phenylalanine were used to demonstrate the versatility of the synthetic route, and that 
no epimerisation occurs.  Thus, the tridentate ligands bear C3 symmetry, while the bidentate ligands 
have C1 symmetry.   
 
Introduction:  Amino acids form a cheap and ubiquitous source of chirality, and use has been made of 
amino acids as metal-binding components of ligands for classical coordination chemistry.[1-4]  Free 
amino acids and derivatives thereof have also been used extensively as ligands and chiral auxiliaries in 
a variety of asymmetric syntheses; this field has been reviewed.[5-7]  For example, chiral amino acids 
have been incorporated into phosphine and phosphite ligands for asymmetric catalysis.[8, 9]  However, 
in many cases the amino acids are not incorporated into the ligand via amide bonds, and most of these 
ligands contain other functional groups; also, many bear the chiral amino acids remote from the metal.  
In this project, we sought to prepare ligands which resemble peptides in only having amide bonds as 
functional groups, with the goal that these ligands should be biologically compatible.  The ligands are 
designed to bind to the metal through the deprotonated acid groups of their amino acids. 
 
Incorporation of more than one amino acid into the ligand leads to multiple chiral centres and also to 
multiple charges.  Our final goal is to prepare neutral complexes of divalent and trivalent metals.  Thus, 
we require dianionic and trianionic ligands.  For dianionic ligands, IDA (iminodiacetic acid), which 
resembles glycine, was selected as a basis for the core of the ligands (Figure 1A); however, the NH 
bond can participate in peptide coupling and so the methyl substituted MIDA (methyliminodiacetic 
acid) (Figure 1B) was prepared.  MIDA structurally resembles half an EDTA molecule and was 
reported 60 years ago.[10]  The chelate NTA (nitrilotriacetic acid) (Figure 1C) was selected as the core 
for trianionic ligands, because it is extremely cheap, readily available, and also structurally resembles 
glycine.  Thus, amino acids protected at their C-terminus can be coupled to MIDA and NTA.  We have 
adopted the nomenclature A-[X(OY)]n where A is NTA or MIDA, X is the amino acid, Y is the 
protecting group or H for the free acid, and n = 2 or 3 for MIDA and NTA, respectively.   
 
Figure 1.  Cores of ligands synthesised. 
 
IDA has previously been used as the core of small peptide mimics with several different groups as the 
third substituent on the central nitrogen atom, such as oxycarbonyls.[11, 12] However, until now MIDA 
has not been used as a ligand core.  NTA has previously been used as the core of some C3 symmetric 
ligands based on a similar synthetic procedure to that reported here, with further synthetic steps to form 
oxazolines[13-15] or to reduce the amide groups to amines.[16]  A NTA-based methyl protected ester of 
valine, very similar to some of the compounds prepared in this work, NTA-[Val(OMe)]3, has been 
reported as an intermediate en route to the corresponding oxazoline;[13] the phenylalanine and alanine 
analogues appear in a PhD thesis.[15]  Other C3 symmetric tripodal peptide bundles have been prepared, 
using ammonia as the core,[17] and used as metalloenzyme mimics.[18]  The current interest in C3 
symmetric compounds as biomimetic ligands and catalysts "inspired by nature" has been reviewed.[19]  
Achiral cryptands have recently been reported using NTA in Ugi-type multiple multicomponent 
macrocyclizations.[20, 21]  However, simple amino acid derivatives such as those reported here have not 
been used as ligands.  The protected ligands and the acid ligands described here are previously 
unreported, although the achiral NTA-[Gly(OH)]3 has been mentioned in a 1992 patent without any 
characterisation data.[22]   
 
In order to allow access to a wide range of amino acid-containing ligands, solution phase coupling of 
the free carboxylic acids of the cores MIDA and NTA with C-protected amino acids was adopted.  
Both methyl and benzyl protected esters were used in coupling reactions with NTA, and benzyl esters 
were coupled to MIDA.  Standard coupling conditions from solid phase peptide synthesis were adapted 
for the coupling reactions.  The protected esters were fully characterised and deprotected by standard 
techniques to form the free di- and tri-acids, which have also been fully characterised.  Our synthesis 
has the advantages of using only cheap and safe starting materials, giving access to a small library of 
di- and trianionic chiral ligands, and was conducted by undergraduate students.   
 
Results and Discussion:  Typical solution phase peptide coupling conditions (DCC or HBTU, DMAP, 
NEt3, CH2Cl2 solution, overnight, room temperature) were successfully used to couple the methyl and 
benzyl C-protected amino acids to the carboxylic acids of NTA and MIDA (Scheme 1).  Use of DCC 
as a coupling agent was successful for the methyl esters; however, for the benzyl esters HBTU was 
adopted because DCC coupling led to low yields.  This is presumably due to the steric bulk of the 
benzyl ester, limiting access of the N-terminus of the amino acid to the activated ester for coupling. 
 (1) 
 (2) 
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Scheme 1.  Solution phase coupling to form protected ligands (1) NTA-[X(OMe)]3; (2) 
MIDA-[X(OBz)]2; (3) NTA-[X(OBz)]3. R = H (Gly); CH2CHMe2 (Leu); CH2Ph (Phe); CH2COOMe 
(AspOMe). 
 
The protected products, other than NTA-[Gly(OMe)]3, are soluble in organic solvents such as CH2Cl2, 
and were purified by silica gel chromatography and characterised by NMR and IR spectroscopy and 
high resolution mass spectrometry.  The 1H NMR spectra of these compounds show well-resolved 
coupling constants and all resonances can be unambiguously assigned using a combination of 1 and 2D 
spectra; Figure 2 shows a typical example.  This indicates that no epimerisation occurs under the 
coupling conditions. This is to be expected using conditions adapted from solid phase peptide 
synthesis.  Methyl-protected D,L phenylalanine was used in one reaction to verify that an epimerised 
amino acid leads to a mixture of diastereomers after coupling.  In that case the 1H NMR spectrum of 
the resulting NTA-[Phe(OMe)]3 was very complicated and the coupling constants were not resolved. 
 
Figure 2.  1H NMR spectrum of NTA-[Leu(OBz)]3 in CDCl3.  The inset shows the resolved coupling 
of the benzylic protons and the α-proton of the amino acid. The resonance at 5.29 is residual CH2Cl2. 
 
Deprotection of the six methyl esters of the protected NTA-[Asp(OMe)(OMe)]3 was achieved using 
1.0M NaOH or LiOH solution (Scheme 2) to form the alkali metal salt of the C3 ligand.  These salts 
were not suitable for use in metal complexation studies with higher valent metals because the alkali 
metals were difficult to remove.  Thus, the methyl esters were not pursued further. 
 
Scheme 2.  Deprotection of NTA-[Asp(OMe)(OMe)]3 with NaOH or LiOH (M = Na or Li). 
 
The benzyl esters were removed by hydrogenolysis over Pd/C (Scheme 3) in ethanol; the protected 
phenyl alanine derivatives MIDA-[Phe(OBz)]2 and NTA-[Phe(OBz)]3 are only sparingly soluble in 
ethanol but this did not affect the reaction.  The solubility of the products of hydrogenolysis is 
substantially different from the protected compounds; none are soluble in CH2Cl2, and all are 
somewhat soluble in water.  The glycine derivatives MIDA-[Gly(OH)]2 and NTA-[Gly(OH)]3 are 
extremely hygroscopic and could only be isolated as powders when not exposed to air; upon air 
exposure, they became sticky oils. 
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Scheme 3.  Deprotection of benzyl protected ligands by hydrogenolysis to form free acids (1) 
MIDA-[X(OH)]2; (2) NTA-[X(OH)]3. 
 
The NMR spectra of the free acids were recorded in D2O, acetone-d6 or DMSO-d6.  The resolved 
coupling constants observed in the 1H NMR spectra indicate that no epimerisation occurred during 
hydrogenolysis, so the newly prepared ligands have C3 and C1 symmetry for the NTA and MIDA cores, 
respectively.   
 
Conclusion:  We have demonstrated a cheap, simple and reliable route to the synthesis of a small 
library of chiral C1 dianionic and C3 trianionic chelating ligands, based on MIDA and NTA cores 
respectively, with amino acid substituents.  Benzyl esters were the most suitable protecting groups for 
the amino acids because upon deprotection, the free acids are formed.  The metal complexation 
behaviour and acidity of these ligands are currently under investigation. 
 
Experimental Section:   
General:   
HBTU, DCC, Leu(OBz).TsOH and Phe(OBz).HCl were purchased from NovaBioChem.  All other 
chemicals and solvents including dimethylaminopyridine (DMAP), triethylamine (NEt3) and palladium 
over carbon (Pd/C) were purchased from Aldrich.  Gly(OBz).TsOH was prepared according to the 
reported method using BzOH and TsOH in C6H6.[23]  The hydrochloric acid salts of the methyl 
protected amino acids Gly(OMe).HCl, Leu(OMe).HCl, Phe(OMe).HCl and Asp(OMe)(OMe).HCl 
were prepared from the free amino acids by stirring overnight at room temperature in methanol with 
two equivalents of thionyl chloride, followed by removal of all volatile material under vacuum.  Silica 
gel 60, 0.04 - 0.06 mm (230-400 mesh) from Scharlau was used for flash column chromatography.  
Eluents were optimised by TLC on silica gel 60 F254 sheets from Merck.  A PMA in EtOH dip followed 
by charring with a hot air gun was used to visualise TLC plates.  NMR spectra were collected on 
Bruker AMX-300, DRX-400 and DRX-500 instruments at room temperature in the solvent specified 
and are referenced to residual protons of the proteosolvent for 1H spectra, or to the carbon of the 
solvent for 13C{1H} spectra.  Assignments are based on a combination of 1 and 2D spectra.  Infrared 
spectra were collected on a Perkin-Elmer 1600 or 1000 FTIR using CsF plates or in solution as 
specified, and only carbonyl stretches are reported.  High resolution mass measurements were obtained 
from a Finnigan MAT 900 XL-Trap electrospray (ESI) mass spectrometer with a Finnigan API III 
electrospray source.  Low resolution ESI mass spectrometry was conducted on a Quattro II triple-
quadruple liquid chromatography-mass spectrometer (Micromass, Manchester, UK) or a Finnigan 
MAT 900 XL-Trap electrospray mass spectrometer with a Finnigan API III electrospray source. 
 
Synthesis of MIDA (modification of a reported technique[10]):   
Iminodiacetic acid (6.65 g, 0.05 mol) was weighed into a round-bottomed flask equipped with a 
magnetic stirrer bar.  Water (6.7 mL, 0.38 mol), formic acid (3.8 mL, 0.10 mol) and formaldehyde (7.5 
mL, 0.27 mol) were added and the mixture was stirred overnight at reflux.  Ethanol (50 mL) was added 
to the resulting pale yellow solution, leading to the formation of a white precipitate, which was 
collected by filtration and washed with ethanol.  Yield: 4.18 g (57%). 
1H NMR (500 MHz, 298 K, D2O): 3.83 (s, 4H, MeNCH2), 2.87 (s, 3H, NMe) (carboxylic acid protons 
not observed). 
13C{1H} NMR (125 MHz, 298 K, D2O): 169.1 (COOH), 57.3 (MeNCH2), 42.4 (NMe). 
 
Typical conditions for coupling benzyl-protected amino acids to MIDA: 
MIDA (1.10 g, 6.8 mmol) and HBTU (5.69 g, 15 mmol, 2.2 equiv) were weighed into a flask equipped 
with a magnetic stirrer bar and dichloromethane (50 mL) was added, followed by DMAP (0.138 g, 1.5 
mmol, 0.22 equiv), NEt3 (4.17 mL, 30 mmol, 4.4 equiv) and the benzyl ester of the amino acid to be 
coupled (15 mmol, 2.2 equiv).  The mixture was stirred overnight at room temperature, after which it 
was a yellow solution.  If a solid precipitated, this was removed by filtration.  The product was purified 
using silica gel chromatography (CH2Cl2:MeOH 96:4).  Yield: 45-60% after chromatography.  The 
later column fractions were sometimes contaminated with tetramethylurea, a byproduct of coupling by 
HBTU. 
Me2NCONMe2: 1H NMR (500 MHz, 298 K, CDCl3): 2.71 (s, NMe2). 13C{1H} NMR (126 MHz, 298 
K, CDCl3): 165.4 (CO), 38.3 (NMe2). 
 
MIDA-[Gly(OBz)]2:  
IR (CsF): 1747, 1660 cm-1. 
1H NMR (400 MHz, 298 K, CDCl3): 7.40 (t, 2H, 3JHH = 5.8 Hz, NH), 7.33 - 7.30 (m, 10H, CH2C6H5), 
5.12 (4H, CH2C6H5), 4.09 (d, 4H, 3JHH = 5.8 Hz, NHCH2), 3.17 (s, 4H, MeNCH2), 2.44 (s, 3H, NMe). 
13C{1H} NMR (101 MHz, 298 K, CDCl3): 170.3 (CO), 170.0 (CO), 135.0 (ipso-C of C6H5), 128.6, 
128.5, 128.3 (ortho, meta, para-C of C6H5), 67.2 (CH2C6H5), 61.2 (MeNCH2), 43.9 (NMe), 40.8 
(NHCH). 
M/S (ESI+): m/z 480 [M+K], 464 [M+Na], 442 [M+H]. 
HRESI-MS: m/z Calculated for C23H28N3O6 442.1973 [M+H]; found 442.1980. 
 
MIDA-[Leu(OBz)]2:  
1H NMR (500 MHz, 298 K, CDCl3): 7.28 (m, 10H, Bz), 7.20 (br d, 2H, 3JHH = 8.6 Hz, NH), 5.12 (d, 
2H, 2JHH = 27 Hz, CH2Ph), 5.07 (d, 2H, 2JHH = 27 Hz, CH2Ph), 4.64 (m, 2H, NHCH), 3.15 (d, 2H, 2JHH 
= 15 Hz, MeNCH2), 3.02 (d, 2H, 2JHH = 15 Hz, MeNCH2), 2.36 (s, 3H, NMe), 1.61 (m, 2H, CHMe2), 
1.55 (m, 4H, CHCH2CH), 0.87 (d, 6H, 3JHH = 1.7 Hz, CHMe), 0.86 (d, 6H, 3JHH = 1.7 Hz, CHMe). 
13C{1H} NMR (125 MHz, 298 K, CDCl3): 172.6 (COOCH2Ph), 169.7 (CONH), 135.1 (ipso-C of 
C6H5), 128.1, 127.9, 127.7 (ortho, meta, para-C of C6H5), 66.5 (CH2C6H5), 60.7 (MeNCH2), 50.1 
(NHCH), 43.2 (NMe), 40.4 (CHCH2CH), 24.5 (CHMe2), 22.5 (CHMe), 21.2 (CHMe). 
M/S (ESI+): m/z 1129 [2M+Na], 576 [M+Na], 554 [M+H]. 
HRESI-MS: m/z Calculated for C31H43N3O6Na: 576.3050 [M+Na]; found 576.3047. 
 
MIDA-[Phe(OBz)]2:  
IR (CsF): 1741, 1663 cm-1. 
1H NMR (400 MHz, 298 K, CDCl3): 7.33 - 7.01 (m, 22H, Ph and NH), 5.17 (d, 2H, 2JHH = 12 Hz, 
OCH2Ph), 5.11 (d, 2H, 2JHH = 12 Hz, OCH2Ph), 4.90 (m, 2H, NHCH), 3.19 - 2.92 (m, 8H MeNCH2 
and CHCH2Ph), 2.13 (s, 3H, NMe). 
13C{1H} NMR (101 MHz, 298 K, CDCl3): 171.6 (COOCH2Ph), 169.4 (CONH), 135.9 and 135.1 (ipso-
C of C6H5), 129.1, 128.6, 128.6, 128.5, 128.5, 127.0 (ortho, meta, para-C of C6H5), 67.3 (OCH2C6H5), 
61.2 (MeNCH2), 52.8 (NHCH), 43.6 (NMe), 37.6 (CHCH2Ph). 
M/S (ESI+): m/z 622.4 [M+H].  
HRESI-MS: m/z Calculated for C37H39N3O6Na: 644.2731 [M+Na]; found 644.2729. 
 
Typical coupling conditions of benzyl esters to NTA: 
The solids NTA (0.15 g, 0.76 mmol), and HBTU (0.96 g, 2.54 mmol. 3.3 equiv) were placed in a flask 
equipped with a magnetic stirrer bar.  Dichloromethane (50 mL) was added, followed by DMAP (0.062 
g, 0.51 mmol, 0.67 equiv), NEt3 (1.42 mL, 10.2 mmol, 13 equiv) and the benzyl protected amino acid 
(2.54 mmol, 3.3 equiv).  The mixture was stirred overnight at room temperature, then washed with 
dilute HCl (1.0 M) and NaHCO3 (1.0 M) followed by distilled water.  The product was purified by 
silica gel chromatography (CH2Cl2:MeOH 96:4).  Yield: 40 - 60% after chromatography.  The later 
column fractions were sometimes contaminated with tetramethylurea, a byproduct of coupling by 
HBTU. 
 
NTA-[Gly(OBz)]3:  
1H NMR (300 MHz, 298 K, CDCl3): 7.67 (t, 3H, 3JHH = 6.0 Hz, NH), 7.31 (m, 15H, CH2C6H5), 5.12 (s, 
6H, CH2C6H5), 4.06 (d, 6H, 3JHH = 6.0 Hz, NHCH2), 3.37 (s, 6H, NCH2). 
13C{1H} NMR (125 MHz, 298 K, CDCl3): 170.5 (NHCO and COOBz), 135.1 (ipso-C of C6H5), 128.7, 
128.6, 128.3 (ortho, meta, para-C of C6H5), 67.3 (CH2C6H5), 58.6 (NCH2), 41.1 (NHCH2). 
M/S (ESI+): m/z 655 [M+Na].  
HRESI-MS: m/z Calculated for C33H36N4O9Na: 655.2380 [M+Na]; found 655.2371. 
 
NTA-[Leu(OBz)]3:  
IR (CsF):  1746, 1666 cm-1. 
1H NMR (300 MHz, 298 K, CDCl3): 7.77 (d, 3H, 3JHH = 8.4 Hz, NH), 7.35 (m, 15H, CH2C6H5), 5.20 
(d, 3H, 2JHH = 12 Hz, CH2Ph), 5.11 (d, 3H, 2JHH = 12 Hz, CH2Ph), 4.65 (m, 3H, NHCH), 3.41 (d, 3H, 
2JHH = 15 Hz, NCH2), 3.25 (d, 3H, 2JHH = 15 Hz, NCH2), 1.73 - 1.57 (m, 9H, CHMe2 and CHCH2CH), 
0.92 (d, 9H, 3JHH = 3.4 Hz, CHMe), 0.90 (d, 9H, 3JHH = 3.4 Hz, CHMe). 
13C{1H} NMR (125 MHz, 298 K, CDCl3): 174.7 (NHCO and COOBz), 140.1 (ipso-C of C6H5), 128.7, 
127.8, 127.4 (ortho, meta, para-C of C6H5), 63.8 (CH2C6H5), 58.5 (NCH2), 52.9 (NHCH), 39.6 
(CHCH2CH), 24.0 (CHMe2), 21.8 (CHMe), 20.8 (CHMe). 
M/S (ESI+): m/z 823 [M+Na], 801 [M+H]. 
HRESI-MS: m/z Calculated for C45H61N4O9: 801.4433 [M+H]; found 801.4422. 
 
NTA-[Phe(OBz)]3:  
IR (CsF): 1732, 1660 cm-1. 
1H NMR (400 MHz, 298 K, CDCl3): 7.60 (d, 3H, 3JHH = 8.4 Hz, NH), 7.35 - 7.12 (m, 30H, C6H5), 5.19 
(d, 3H, 2JHH = 12.2 Hz, OCH2Ph), 5.13 (d, 3H, 2JHH = 12.2 Hz, OCH2Ph), 4.90 (m, 3H, NHCH), 3.19 - 
2.91 (m, 12H, NCH2 and CHCH2Ph). 
13C{1H} NMR (100 MHz, 298 K, CDCl3): 172.6 (COOBz), 170.1 (NHCO), 136.1 and 135.0 (ipso-C of 
C6H5), 129.0, 128.5, 128.4, 128.4, 128.2, 126.9 (ortho, meta, para-C of C6H5), 67.3 (OCH2C6H5), 57.6 
(NCH2), 53.4 (NHCH), 37.3 (CHCH2Ph). 
M/S (ESI+): m/z 903 [M+H]. 
HRESI-MS: m/z Calculated for C54H55N4O9: 903.3964 [M+H]; found 903.3962. 
 
Typical coupling conditions of methyl esters to NTA: 
The solids NTA (0.27 g, 1.41 mmol), and DCC (1.05 g, 5.10 mmol. 3.6 equiv) were placed in a flask 
equipped with a magnetic stirrer bar under nitrogen.  Distilled dichloromethane (50 mL) was added, 
followed by DMAP (0.12 g, 0.98 mmol, 0.7 equiv), triethylamine (1.29 mL, 9.27 mmol, 6.6 equiv) and 
the methyl protected amino acid (4.63 mmol, 3.3 equiv).  The mixture was stirred under nitrogen 
overnight at room temperature, then filtered and washed with dilute acid followed by distilled water.  
The product was purified by silica gel chromatography (CH2Cl2:MeOH 96:4).  Yield: 40 - 60% after 
chromatography. 
 NTA-[Gly(OMe)]3:  
1H NMR (500 MHz, 298 K, CDCl3): 7.77 (br t, 3H, 3JHH = 3.4 Hz, NH), 4.04 (d, 6H, 3JHH = 3.6 Hz, 
NHCH2), 3.71 (s, 9H, OMe), 3.39 (s, 6H, NCH2). 
1H NMR (500 MHz, 298 K, D2O): 3.98 (s, 6H, NHCH2), 3.67 (s, 9H, OMe), 3.44 (s, 6H, NCH2). 
13C{1H} NMR (125 MHz, 298 K, CDCl3): 171.2 (COOMe), 170.9 (NHCO), 58.7 (NCH2), 52.4 
(COOMe), 40.8 (NHCH2). 
13C{1H} NMR (125 MHz, 298 K, D2O): 173.1 (COOMe), 171.4 (NHCO), 57.1 (NCH2), 52.3 
(COOMe), 40.5 (NHCH2). 
M/S: m/z 427 [M+Na]. 
 
NTA-[Phe(OMe)]3 (mixture of diastereomers) (reported in a PhD thesis[15]): 
IR (CH2Cl2 solution): νCO = 1738, 1680 cm-1. 
1H NMR (300 MHz, 298 K, CDCl3): 7.36 - 7.08 (m, 18H, NH and C6H5), 4.79 (m, 3H, NHCH), 3.72 
(s, 9H, OMe), 3.25 - 2.90 (m, 12H, CH2Ph and NCH2).  
M/S (ESI+): m/z 697 [M+Na], 675 [M+H]. 
HRESI-MS: m/z Calculated for C36H42N4O9Na [M+Na]: 697.2849; Found 697.2839. 
 
NTA-[Leu(OMe)]3:  
IR (MeOH solution): νCO = 1749, 1664 cm-1. 
1H NMR (300 MHz, 298 K, CDCl3): 7.71 (br d, 3H, 3JHH = 8.5 Hz, NH), 4.60 (m, 3H, NHCH), 3.71 (s, 
9H OMe), 3.41 (d, 3H, 2JHH = 15 Hz, NCH2), 3.20 (d, 3H, 2JHH = 15 Hz, NCH2), 1.74 - 1.56 (m, 9H, 
CHMe2 and CHCH2CH), 0.92 (d, 9H, 3JHH = 2.4 Hz, CHMe), 0.90 (d, 9H, 3JHH = 2.3 Hz, CHMe). 
13C{1H} NMR (75 MHz, 298 K, CDCl3): 174.9 (COOMe), 170.5 (CONH), 58.2 (NCH2), 52.4 (OMe), 
50.6 (NHCH), 40.3 (CHCH2CH), 24.8 (CHMe2), 23.0 (CHMe), 21.3 (CHMe). 
M/S (ESI+): m/z 1167 [2M+Na], 1145 [2M+H], 595 [M+Na], 573 [M+H]. 
HRESI-MS: m/z Calculated for C27H48N4O9Na [M+Na]: 595.3319; Found 595.3306. 
 
NTA-[Asp(OMe)(OMe)]3:  
IR (CH2Cl2 solution): νCO = 1737, 1681 cm-1. 
1H NMR (500 MHz, 298 K, CDCl3): 7.72 (d, 3H, 3JHH = 8.6 Hz, NH), 4.92 (m, 3H, NHCH), 3.71 (s, 
9H, OMe), 3.66 (s, 9H, OMe), 3.46 (d, 3H, 2JHH = 15 Hz, NCH2), 3.24 (d, 3H, 2JHH = 15 Hz, NCH2), 
2.99 (dd, 3H, 2JHH =  17 Hz, 3JHH = 6.0 Hz, CHCH2CO), 2.88 (dd, 3H, 2JHH = 17 Hz, 3JHH = 4.7 Hz, 
CHCH2CO). 
13C{1H} NMR (125 MHz, 298 K, CDCl3): 171.5 (COOMe), 171.2 (COOMe), 169.8 (NHCO), 58.4 
(NCH2), 52.8 (OMe), 52.1 (OMe), 48.4 (NHCH), 35.8 (CHCH2CO). 
M/S (ESI+): m/z 643 [M+Na], 621 [M+H]. 
HRESI-MS: m/z Calculated for C24H36N4O15Na [M+Na]: 643.2075; Found 643.2082. 
 
Typical deprotection conditions for benzyl esters:  
A small amount of Pd/C (ca. 2 mg) was added to an ethanol (50 mL) solution or suspension of the 
compound (ca. 400 mg).  The mixture was subjected to a hydrogen atmosphere from a balloon with 
stirring (NTA-[Gly(OBz)]3, NTA-[Leu(OBz)]3, MIDA-[Leu(OBz)]2), or using a Parr hydrogenator, 30 
psi were applied (NTA-[Phe(OBz)]3, MIDA-[Gly(OBz)]2, MIDA-[Phe(OBz)]2).  After stirring for 1 
hour, the solution was filtered through Celite and the solvent was removed in vacuo.  The free acids of 
the glycine derivatives MIDA-[Gly(OH)]2 and NTA-[Gly(OH)]3 are extremely hygroscopic so no yield 
was recorded.  For the other free acids, yields were above 80%. 
 
MIDA-[Gly(OH)]2:  
1H NMR (300 MHz, 298 K, D2O): 4.01 (s, 4H, CH2COOH), 3.80 (s, 4H, MeNCH2), 2.88 (s, 3H, 
NMe). 
13C{1H} NMR (100 MHz, 298 K, D2O): 175.0 (COOH), 166.1 (CONH), 57.6 (MeNCH2), 43.5 (NMe), 
42.7 (NHCH2). 
M/S (ESI+): m/z 561 [2M+K], 545 [2M+Na], 284 [M+Na], 262 [M+H]. 
HRESI-MS: m/z Calculated for C9H15N3O6Na: 284.0859 [M+Na]; Found: 284.0868. 
Due to the hygroscopic nature of this compound, no infrared spectrum could be obtained. 
 
MIDA-[Leu(OH)]2:  
1H NMR (300 MHz, 298 K, D2O): 8.49 (br d, 2H, 3JHH = 12 Hz, NH), 4.17 (m, 2H, NHCH), 3.96 (s, 
4H, MeNCH2), 2.86 (s, 3H, NMe), 1.49 (m, 6H, CHMe2 and CHCH2CH), 0.77 (d, 6H, 3JHH = 10 Hz, 
CHMe), 0.74 (d, 6H, 3JHH = 10 Hz, CHMe). 
13C{1H} NMR (75 MHz, 298 K, D2O): 177.7 (COOH), 164.8 (CONH), 56.8 (MeNCH2), 52.9 
(NHCH), 42.8 (NMe), 39.7 (CHCH2CH), 24.5 (CHMe2), 22.2 (CHMe), 20.6 (CHMe). 
M/S (ESI+): m/z 769 [2M+Na], 747 [2M+H], 396 [M+Na], 374 [M+H]. 
HRESI-MS: m/z Calculated for C17H31N3O6Na: 396.2111 [M+Na]; Found: 396.2116. 
 MIDA-[Phe(OH)]2:  
IR (CsF): 1667 cm-1. 
1H NMR (400 MHz, 298 K, DMSO-d6): 8.25 (br, 2H, NH), 7.20 (m, 10H, C6H5), 4.50 (ddd, 3JHH = 9.0 
Hz, 3JHH = 9.0 Hz, 3JHH = 4.8 Hz, 2H, NHCH), 3.11 (dd, 2H, 2JHH = 13.8 Hz, 3JHH = 4.8 Hz, CH2Ph), 
3.01 (br, 4H, NCH2), 2.91 (dd, 2H, 2JHH = 13.8 Hz, 3JHH = 9.7 Hz, CH2Ph), 2.03 (br s, NMe) (COOH 
not observed). 
13C{1H} NMR (100 MHz, 298 K, DMSO- d6): 172.9 (CONH), 169.2 (br, COOH), 137.7 (ipso-C of 
C6H5), 129.2, 128.3, 126.5, (ortho, meta, para-C of C6H5), 59.9 (br, NCH2), 53.2 (NHCH), 42.2 
(NMe), 36.6 (CH2Ph). 
M/S (ESI+): m/z 442.2 [M+H]. 
HRESI-MS: m/z Calculated for C23H28N3O6: 442.1973 [M+H]; Found: 442.1965. 
 
NTA-[Gly(OH)]3:  
IR (THF solution): 1752, 1684 cm-1. 
1H NMR (300 MHz, 298 K, D2O): 3.92 (s, 6H, NHCH2), 3.50 (s, 6H, NCH2) (COOH not observed). 
M/S (ESI+): m/z 385 [M+Na].  
 
NTA-[Leu(OH)]3:  
1H NMR (500 MHz, 298 K, D2O): 7.32 (m, 3H, NH), 4.31 (m, 3H, NHCH), 3.39 (s, 6H, NCH2), 1.62 - 
1.52 (m, 9H, CHMe2 and CHCH2CH), 0.83 (d, 9H, 3JHH = 3.6 Hz, CHMe), 0.79 (d, 9H, 3JHH = 3.5 Hz, 
CHMe) (COOH not observed). 
13C{1H} NMR (125 MHz, 298 K, D2O): 176.3 (COOH), 172.7 (CONH), 57.7 (NCH2), 51.4 (NHCH), 
39.3 (CHCH2CH), 24.4 (CHMe2), 22.2 (CHMe), 20.4 (CHMe). 
M/S (TOF+): 531 [M+H]. 
 
NTA-[Phe(OH)]3:  
IR (CsF): 1659 cm-1. 
1H NMR (400 MHz, 298 K, acetone-d6): 8.1 (br, not integrated, NH), 7.23 - 7.08 (m, 15H, C6H5), 4.67 
(dd, 3H, 3JHH = 9.6 Hz, 3JHH = 4.5 Hz, NHCH), 3.19 (dd, 3H, 2JHH = 13.9 Hz, 3JHH = 4.5 Hz, CH2Ph), 
2.91 (m, 9H, CH2Ph and NCH2) (COOH not observed). 
1H NMR (400 MHz, 298 K, DMSO-d6): 8.32 (br, 3H, NH), 7.22 - 7.12 (m, 15H, C6H5), 4.54 (br dd, 
3H, NHCH), 3.12 (dd, 3H, 2JHH = 13.7 Hz, 3JHH = 4.3 Hz, CH2Ph), 2.87 (br, 9H, NCH2 and CH2Ph) 
(COOH not observed). 
1H NMR (400 MHz, 298 K, D2O): 7.22 (m, 15H, C6H5), 4.65 (br dd, 3H, NHCH), 3.30 (dd, 3H, 2JHH = 
14.2 Hz, 3JHH = 4.1 Hz, CH2Ph), 2.91 (dd, 3H, 2JHH = 13.7 Hz, 3JHH = 10.3 Hz, CH2Ph), 2.57 (d, 3H, 
2JHH = 16.8 Hz, NCH2), 2.51 (d, 3H, 2JHH = 16.1 Hz, NCH2) (NH and COOH not observed). 
13C{1H} NMR (100 MHz, 298 K, acetone- d6): 174.1 (COOH), 171.1 (CONH), 138.3 (ipso-C of C6H5), 
130.0, 129.1, 127.4 (ortho, meta, para-C of C6H5), 58.3 (NCH2), 54.3 (NHCH), 37.8 (CH2Ph). 
M/S (ESI+): m/z 655.4 [M+Na].  
HRESI-MS: m/z Calculated for C33H36N4O9Na: 655.2376 [M+Na]; Found: 655.2367. 
 
Deprotection conditions for NTA-[Asp(OMe)(OMe)]3:   
0.50 g (0.81 mmol) of the methyl ester was weighed into a round bottomed flask and 10 mL of distilled 
water were added.  The ester was not completely soluble.  Six equivalents of the metal hydroxide 
(NaOH or LiOH) per NTA were weighed into a separate flask and dissolved in water.  The base was 
added to the ester and the mixture was stirred overnight at room temperature.  The water was removed 
under vacuum leaving a hygroscopic white solid which was insoluble in alcohols or THF.  
 
NTA-[Asp(ONa)(ONa)]3:  
1H NMR (500 MHz, 298 K, D2O): 4.30 (dd, 3H, 3JHH = 9.9 Hz, 3JHH = 3.9 Hz, NHCH), 3.30 (s, 6H, 
NCH2), 2.54 (dd, 3H, 2JHH = 16 Hz, 3JHH = 4.0 Hz, CHCH2), 2.35 (dd, 3H, 2JHH = 16 Hz, 3JHH = 10 Hz, 
CHCH2). 
13C{1H} NMR (125 MHz, 298 K, D2O): 178.8 (COONa), 178.5 (COONa), 172.3 (CONH), 56.6 
(NCH2), 53.0 (NHCH), 39.5 (CHCH2). 
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